Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ravidasvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ravidasvir SCHEMBL31554846 | 1.00 | CYP3A4 (0.73) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| Ravidasvir SCHEMBL2709449 | 1.00 | CYP3A4 (0.73) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| Ravidasvir SCHEMBL16907904 | 1.00 | CYP3A4 (0.73) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| Ravidasvir SCHEMBL10176873 | 1.00 | CYP3A4 (0.73) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL7605300 | 0.98 | CYP3A4 (0.71) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12104404 | 0.98 | CYP3A4 (0.72) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12107402 | 0.98 | CYP3A4 (0.78) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12075681 | 0.97 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12004034 | 0.97 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12061902 | 0.96 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017021270-A1 | PROCESS FOR THE SYNTHESIS OF RAVIDASVIR | HC-PHARMA AG (CH) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2010065674-A9 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | CYP3A4 1005/4885CYP2C9 2691/4885NR1I2 1317/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP3A4 2538/4885CYP2C9 3984/4885NR1I2 1398/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | CYP3A4 1690/4885CYP2C9 3351/4885NR1I2 1716/4885 |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | HAVCR2, CBR3, ZC3HAV1 | CYP3A4 38/4885CYP2C9 338/4885NR1I2 25/4885 |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | HAVCR2, CBR3, ZC3HAV1 | CYP3A4 38/4885CYP2C9 338/4885NR1I2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.